Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640700 | 0.93 | DHFR (0.57) | DHFRCA1CA2CA9SLC19A1 | |
| SCHEMBL480952 | 0.85 | DHFR (0.64) | DHFRCA1CA2CA9SLC19A1 | |
| SCHEMBL479220 | 0.84 | DHFR (0.54) | DHFRCA1CA2CA9 | |
| SCHEMBL24344106 | 0.84 | DHFR (0.70) | DHFRCA1CA2CA9SLC19A1 | |
| SCHEMBL30433670 | 0.84 | DHFR (0.70) | DHFRCA1CA2CA9SLC19A1 | |
| SCHEMBL13186879 | 0.82 | DHFR (0.61) | DHFRCA1CA2CA9SLC19A1 | |
| SCHEMBL13186883 | 0.81 | DHFR (0.50) | DHFRCA1CA2CA9 | |
| SCHEMBL14417311 | 0.79 | DHFR (0.81) | DHFRCA1CA2CA9 | |
| SCHEMBL28985427 | 0.78 | DHFR (0.80) | DHFRCA1CA2CA9 | |
| SCHEMBL479181 | 0.78 | DHFR (0.72) | DHFRCA1CA2CA9SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2410856-A1 | DIAMINOPTERIDINE DERIVATIVES | Biorelix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | MPO, AOC1, DCTD | DHFR 19/4885CA1 4547/4885CA2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.